Alterations of gut microbiota and metabolome in early chronic kidney disease patients complicated with hyperuricemia
نویسندگان
چکیده
ObjectThis study aims to investigate the changes in gut microbiota and metabolism of patients with chronic kidney disease (CKD) stage 1–2, as well potential impact hyperuricemia (HUA) on these factors CKD 1–2 patients.MethodsIn this study, fecal samples were collected from without HUA (CKD-N group), (CKD-H healthy people controls (HCs group). The then subjected microbiome (16S rRNA gene sequencing) metabolome (liquid chromatography-tandem mass spectrometry) analyses. multi-omics datasets analyzed individually integrated for combined analysis using various bioinformatics approaches.ResultsGut microbial dysbiosis was found CKD-N CKD-H patients. At phylum level, compared HCs group, Bacteroidetes decreased but Proteobacteria increased group significantly. Fusobacteria significantly lower than group. genus [Eubacterium]_ventriosum_group, Fusobacterium, Agathobacter, Parabacteroides, Roseburia changed groups. [Ruminococcus]_gnavus_group Moreover, altered d-glutamine d-glutamate metabolism, arginine proline histidine lysine biosynthesis down-regulated Phenylalanine purine beta-alanine up-regulated There a significant difference between two groups phenylalanine metabolism. abundance change [Ruminococcus]_gnavus_group, UCG-002, Alistipes, Bifidobacterium had close correlation differential metabolites.ConclusionThe metabolic status undergo people. Additionally, has been patients, their association metabolites suggests that former plays crucial role
منابع مشابه
Gut microbiota and inflammation in chronic kidney disease patients
Inflammation is a multifactorial phenotype that in chronic kidney disease is associated with adverse patient outcomes. Recently, alterations in gut microbiota composition and intestinal barrier have been associated with inflammation and oxidative stress in CKD patients. Vanholder and Glorieux recently critically reviewed [Clin Kidney J (2015) 8 (2): 168-179] the current understanding of the rol...
متن کاملFebuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
Febuxostat is a nonpurine xanthine oxidase (XO) inhibitor, which recently received marketing approval. However, information regarding the experience with this agent among advanced chronic kidney disease (CKD) patients is limited. In the current study, we investigated the effects of oral febuxostat in patients with advanced CKD with asymptomatic hyperuricemia. We demonstrated, for the first time...
متن کاملHyperuricemia is associated with progression of chronic kidney disease in patients with reduced functioning kidney mass.
BACKGROUND AND OBJECTIVES Hyperuricemia plays a major role in the development and progression of chronic kidney disease (CKD). Many large observational studies have indicated that increased serum uric acid level predicts the development and progression of CKD in some population, however this hypothesis has not been yet studied in patients with reduced renal mass. DESIGN, SETTING, PARTICIPANTS...
متن کاملAttention deficit hyperactivity disorder in children with early stages of chronic kidney disease
Background :Attention Deficit Hyperactivity Disorder (ADHD) is the most common childhood neurological disorder. This disorder is more prevalent in some chronic diseases. The aim of this study was to investigate ADHD in children with early stages of chronic kidney disease (CKD) and to compare it with healthy children. Methods : Seventy five 5-16-year-old children with early stages of CKD (st...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Heliyon
سال: 2023
ISSN: ['2405-8440']
DOI: https://doi.org/10.1016/j.heliyon.2023.e20328